Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02981069 · ClinicalTrials.gov registry record · Phase 4
Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM
A Phase 4 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT02981069 is a Phase 4 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 90 participants.
The verdict
NCT02981069, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous glucose production) and plasma glucose concentration in diabetic subjects. Researchers will examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concentration.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
- DRUG Exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2023-03-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02981069
The ClinicalTrials.gov registry entry for NCT02981069 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02981069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02981069 about?
NCT02981069 is a clinical study titled "Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM". In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous glucose production) and plasma glucose concentration in diabetic subjects. Researchers will examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concent...
What is the current status of trial NCT02981069?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2017-12-15. Estimated completion is 2023-03-19.
What interventions are being tested in trial NCT02981069?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG), Exenatide (DRUG).
Who is sponsoring clinical trial NCT02981069?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.